Peter Sturtevant

The COVID-19 pandemic is currently top of mind among pharma professionals, but stakeholders have other business to attend to – such as the upcoming deadline to meet regulatory requirements of the US FDA’s 2013 Drug Supply Chain Security Act.

A new assessment shows year-over-year improvements on meeting DSCSA serialization requirements, which indicate the industry is making steady progress.

Despite delay in enforcement of Drug Supply Chain Security Act's new serialization requirement, getting compliant now is key.